bendamustine hydrochloride has been researched along with Herpes Zoster in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Alderuccio, JP; Alexander, JS; Alpert, AB; Arcaini, L; Argnani, L; Ayyappan, S; Beaven, AW; Castillo, JJ; Cencini, E; Chowdhury, SM; Edwards, D; Epperla, N; Friedberg, JW; Gaballa, S; Herrera, AF; Hess, B; Kahl, BS; Kamdar, M; Kim, SH; Kwon, D; Link, BK; Logothetis, CN; Lossos, IS; Luminari, S; Martin, P; Olszewski, AJ; Reis, IM; Saba, R; Sandoval-Sus, J; Shouse, G; Spina, M; Stefanovic, A; Torka, P; Vargas, F; Voorhees, TJ; Watkins, MP; Zhao, W; Zinzani, PL | 1 |
Kashiwagi, M; Kawai, R; Kawashiri, T; Shimizu, T; Uchida, M; Uesawa, Y | 1 |
Kempf, W; Mitteldorf, C; Tronnier, M; Wollert, E | 1 |
Hamdan, A; Joyce, RM; Tzachanis, D; Uhlmann, EJ | 1 |
4 other study(ies) available for bendamustine hydrochloride and Herpes Zoster
Article | Year |
---|---|
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Herpes Zoster; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Rituximab; Young Adult | 2022 |
Time to Onset of Bendamustine-associated Skin Damage Using the Spontaneous Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Bendamustine Hydrochloride; Drug-Related Side Effects and Adverse Reactions; Exanthema; Herpes Zoster; Humans; Quality of Life | 2022 |
Generalized maculopapular and vesicular rash.
Topics: Acyclovir; Aged; Bendamustine Hydrochloride; Drug Eruptions; Epidermis; Herpes Zoster; Humans; Immunoblastic Lymphadenopathy; Keratinocytes; Lymphocytes; Lymphoma, T-Cell; Male; Programmed Cell Death 1 Receptor; Skin | 2018 |
Successful treatment of refractory Guillain-Barré syndrome with alemtuzumab in a patient with chronic lymphocytic leukemia.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Bendamustine Hydrochloride; CD52 Antigen; Combined Modality Therapy; Consciousness Disorders; Gangliosides; Glycoproteins; Guillain-Barre Syndrome; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunoglobulins, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Miller Fisher Syndrome; Nitrogen Mustard Compounds; Plasmapheresis; Remission Induction; Rituximab; Virus Activation | 2014 |